Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
New York, New York–(Newsfile Corp. – January 24, 2025) – WHY: Rosen Law Firm, a global investment law firm, reminds clients of the securities of Cassava Sciences, Inc. (NASDAQ: NASDAQ: ) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), the relevant February 10, 2025 plaintiff’s deadline.
NOW: If you purchased Cassava securities during the Group period you may be entitled to compensation without paying out-of-pocket fees or expenses through the contingency fee arrangement.
WHAT YOU NEED TO DO: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about a class action. A class action lawsuit has been filed. If you wish to act as the lead plaintiff, you must remove the Court before March 10, 2025. The lead plaintiff is the party representing the other members of the class to conduct the case.
WHY ROSEN LAW: We encourage investors to select qualified advisors with a track record of success in leadership roles. Oftentimes, the companies that issue the notices don’t have the experience, the resources, or any meaningful peer recognition. Most of these firms do not litigate securities class actions, but are simply brokers who refer clients or partner with law firms that litigate the cases. Be smart when choosing advice. The Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder litigation. The Rosen Law Firm achieved the largest defense settlement against a Chinese Company at that time. Rosen Law Firm is ranked No. 1 is the ISS Securities Group Action (WA:) Securities ranking services in 2017. The firm has been ranked 4th every year since 2013 and has earned hundreds of millions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs’ Bar. Most of the firm’s lawyers are recognized by Lawdragon and Super Lawyers.
FACTS OF THE CASE: According to the lawsuit, the defendants throughout the Class Period created a false impression that they had reliable information about Cassava drug opportunities and expected growth while minimizing the risk of drug failure. However, in reality, Cassava’s repeated claims of confidence in simufilam, Cassava’s lead drug candidate, and reliance on the scraping of the anecdotal data from the Phase 2 study fell short. it is the truth of simufilam ability; Cassava did not have a drug that could slow the progression of Alzheimer’s Disease, although it was only trying to treat mild or moderate cases. When the real facts entered the market, the lawsuit alleges that investors were harmed.
To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about a class action.
No Group Guaranteed. Until the group is confirmed, you are not represented by a counselor unless you have reserved one. You can choose a consultant of your choice. You can remain a member of the missing group and do nothing at this point. The investor’s ability to contribute to future recovery does not depend on serving as the primary plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): /www .facebook.com/rosenlawfirm.
Advertising Attorney. Preliminary results do not guarantee a similar outcome.
——————————
To view the source version of this release, please visit https://www.newsfilecorp.com/release/238388
